Overview

Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas

Status:
Not yet recruiting
Trial end date:
2030-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether combining of Temozolomide and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with Advanced Malignant Gliomas. The effectiveness and safety of CIK cells for the treatment of Malignant Glioma is also evaluated.
Phase:
Phase 4
Details
Lead Sponsor:
The First People's Hospital of Changzhou
Treatments:
Dacarbazine
Temozolomide